CI Investments Inc
RARE icon

CI Investments Inc’s Ultragenyx Pharmaceutical RARE Stock Holding History

CI Investments Inc’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,330
Closed -$48K – 1333
2025
Q1 		$48K Sell
1,330
-6
-0.4% -$250 ﹤0.01% 1039
2024
Q4 		$56K Sell
1,336
-241
-15% -$12K ﹤0.01% 1024
2024
Q3 		$88K Buy
1,577
+12
+0.8% +$611 ﹤0.01% 881
2024
Q2 		$64K Buy
1,565
+309
+25% +$13.2K ﹤0.01% 922
2024
Q1 		$59K Buy
1,256
+1
+0.1% +$47 ﹤0.01% 992
2023
Q4 		$60K Buy
+1,255
New +$48.7K ﹤0.01% 935
2022
Q4 		– Sell
-128
Closed -$5K – 1337
2022
Q3 		$5K Sell
128
-9
-7% -$462 ﹤0.01% 1161
2022
Q2 		$8K Sell
137
-29
-17% -$1.78K ﹤0.01% 1052
2022
Q1 		$12K Buy
166
+163
+5,433% +$11.3K ﹤0.01% 1079
2021
Q4 		$0 Hold
3
– – ﹤0.01% 1415
2021
Q3 		$0 Buy
+3
New +$271 ﹤0.01% 1367
2021
Q1 		– Sell
-4,527
Closed -$627K – 1048
2020
Q4 		$627K Buy
+4,527
New +$537K ﹤0.01% 445

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

CI Investments Inc's RARE Position: Q2 2025 in Review

CI Investments Inc sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 1,330 shares — an estimated $48K sold.

CI Investments Inc first reported a position in RARE in Q4 2020 and held it in 12 quarters. The position peaked at $627K in Q4 2020. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

  • CI Investments Inc reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • CI Investments Inc sold 1,330 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $48K.
  • CI Investments Inc first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and held it in 12 quarters.
  • CI Investments Inc's Ultragenyx Pharmaceutical position peaked at $627K in Q4 2020.
  • 309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on CI Investments Inc's 13F filing for Q2 2025, filed 12 Aug 2025.